Loading company…
Milestone Pharmaceuticals develops etripamil, an investigational nasal spray for acute heart rhythm conditions.
Milestone Pharmaceuticals is developing etripamil, a nasal spray for acute at-home treatment of paroxysmal supraventricular tachycardia and atrial fibrillation with rapid ventricular rate. Founded in 2005 in Quebec, Canada, by Philippe Douville, the company was listed on NASDAQ under ticker MIST as of 2024. In February 2024, it raised USD 30 million in a private placement.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in